Pharming announces initiation of clinical phase I/II pre-eclampsia study
Pharming Group N.V. today announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia
''Our strong performance in 2018 and the first quarter of 2019 has enabled us to invest in future growth through the development of our pipeline. Today, following ethics committee approval, we are initiating our first pre-eclampsia study with RUCONEST®''- Sijmen de Vries - CEO
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.